Northwest Biotherapeutics (NWBO) Enterprise Value (2010 - 2026)

Northwest Biotherapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$1.8 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 35.73% year-over-year to -$1.8 million in Q1 2026; TTM through Mar 2026 was -$1.8 million, a 35.73% increase from a year earlier, with the FY2025 full-year figure at -$3.0 million, down 39.77% from the prior year.
• Enterprise Value improved to -$1.8 million in Q1 2026 per NWBO's latest filing, from -$3.0 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$1.4 million in Q2 2023 and bottomed at -$9.4 million in Q3 2022.
• The 5-year median for Enterprise Value is -$3.0 million (2025), against an average of -$4.2 million.
• Across the five-year window, Enterprise Value tumbled 145.7% in 2022 and soared 70.52% in 2023, its largest moves.
• Year by year, Enterprise Value stood at -$7.0 million in 2022, then soared by 69.48% to -$2.1 million in 2023, then decreased by 2.3% to -$2.2 million in 2024, then plunged by 39.77% to -$3.0 million in 2025, then soared by 41.25% to -$1.8 million in 2026.
• Per Business Quant, the three latest NWBO Enterprise Value figures stand at -$1.8 million (Q1 2026), -$3.0 million (Q4 2025), and -$4.6 million (Q3 2025).